Combination of markers for predicting the response to Vx-001
AssigneeKriptic Pharmaceuticals Limited
InventorsKostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.
Claims10
A method of prolonging survival and/or time to failure (TFF) of a HLA-A*0201-positive patient having a lung tumor expressing Telomerase Reverse Transcriptase (TERT) comprising a step of selecting a HLA-A*0201-positive patient having a lung tumor expressing Telomerase Reverse Transcriptase (TERT) and who has a normal level of gamma Glutamine Transferase (gGT) and/or a normal level of lactate dehydrogenase (LDH) and a step of administering a Vx-001 anti-cancer vaccine comprising a peptide of SEQ ID NO:
- 2 and a peptide of SEQ ID NO:
- 1 to the selected patient, wherein the administering of the Vx-001 anti-cancer vaccine to the selected patient prolongs survival and/or TFF of the patient as compared to placebo.
Dependencies are inferred from the claim text.